Search Results - "Puente, Pilar"

Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma by Puente, Pilar, Azab, Abdel Kareem

“…Multiple myeloma (MM) is a hematological malignancy that remains incurable, with relapse rates >90%. The main limiting factor for the effective use of…”
Get full text

Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma by Federico, Cinzia, Alhallak, Kinan, Sun, Jennifer, Duncan, Kathleen, Azab, Feda, Sudlow, Gail P., de la Puente, Pilar, Muz, Barbara, Kapoor, Vaishali, Zhang, Luna, Yuan, Fangzheng, Markovic, Matea, Kotsybar, Joseph, Wasden, Katherine, Guenthner, Nicole, Gurley, Shannon, King, Justin, Kohnen, Daniel, Salama, Noha N., Thotala, Dinesh, Hallahan, Dennis E., Vij, Ravi, DiPersio, John F., Achilefu, Samuel, Azab, Abdel Kareem

“…Drug resistance and dose-limiting toxicities are significant barriers for treatment of multiple myeloma (MM). Bone marrow microenvironment (BMME) plays a major…”
Get full text

A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma by Alhallak, Kinan, Jeske, Amanda, de la Puente, Pilar, Sun, Jennifer, Fiala, Mark, Azab, Feda, Muz, Barbara, Sahin, Ilyas, Vij, Ravi, DiPersio, John F., Azab, Abdel Kareem

“…Cancer patients undergo detrimental toxicities and ineffective treatments especially in the relapsed setting, due to failed treatment attempts. The development…”
Get full text

A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX by Rodríguez-Arbolí, Eduardo, Rodríguez-Veiga, Rebeca, Soria-Saldise, Elena, Bergua, Juan M, Caballero-Velázquez, Teresa, Arnán, Montserrat, Vives, Susana, Serrano, Josefina, Bernal, Teresa, Martínez-Sánchez, Pilar, Tormo, Mar, Rodríguez-Medina, Carlos, Herrera-Puente, Pilar, Lavilla-Rubira, Esperanza, Boluda, Blanca, Acuña-Cruz, Evelyn, Cano, Isabel, Cáceres, Sara, Ballesteros, Juan, Falantes, José, Martínez-Cuadrón, David, Pérez-Simón, José A, Montesinos, Pau

“…LAMVYX was a multicenter, single-arm, phase 2 trial designed to validate the safety and efficacy of CPX-351 in patients aged 60-75 years with newly diagnosed,…”
Get full text

A CD138‐independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma by Muz, Barbara, Puente, Pilar, Azab, Feda, Luderer, Micah John, King, Justin, Vij, Ravi, Azab, Abdel Kareem

“…Summary CD138 (also termed SDC1) has been the gold‐standard surface marker to detect multiple myeloma (MM) cells for decades; however, drug‐resistant residual…”
Get full text

Survival after allogeneic transplantation according to pretransplant minimal residual disease and conditioning intensity in patients with acute myeloid leukemia by Núñez-Torrón Stock, Claudia, Jiménez Chillón, Carlos, Martín Moro, Fernando, Marquet Palomanes, Juan, Piris Villaespesa, Miguel, Roldán Santiago, Ernesto, Rodríguez Martín, Eulalia, Chinea Rodríguez, Anabelle, García Gutiérrez, Valentín, Moreno Jiménez, Gemma, López Jiménez, Javier, Herrera Puente, Pilar

“…The measurement of minimal residual disease (MRD) by multiparametric flow cytometry (MFC) before hematopoietic stem cell transplantation (HSCT) in patients…”
Get full text

Multicompartmentalized Microvascularized Tumor-on-a-Chip to Study Tumor-Stroma Interactions and Drug Resistance in Ovarian Cancer by Plesselova, Simona, Calar, Kristin, Axemaker, Hailey, Sahly, Emma, Bhagia, Amrita, Faragher, Jessica L., Fink, Darci M., de la Puente, Pilar

“…Introduction The majority of ovarian cancer (OC) patients receiving standard of care chemotherapy develop chemoresistance within 5 years. The tumor…”
Get full text

Reduction of Metastasis via Epigenetic Modulation in a Murine Model of Metastatic Triple Negative Breast Cancer (TNBC) by Zylla, Jessica L S, Hoffman, Mariah M, Plesselova, Simona, Bhattacharya, Somshuvra, Calar, Kristin, Afeworki, Yohannes, de la Puente, Pilar, Gnimpieba, Etienne Z, Miskimins, W Keith, Messerli, Shanta M

“…This study investigates the effects of a dual selective Class I histone deacetylase (HDAC)/lysine-specific histone demethylase 1A (LSD1) inhibitor known as…”
Get full text

PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma‐induced resistance by Azab, Feda, Vali, Shireen, Abraham, Joseph, Potter, Nicholas, Muz, Barbara, Puente, Pilar, Fiala, Mark, Paasch, Jacob, Sultana, Zeba, Tyagi, Anuj, Abbasi, Taher, Vij, Ravi, Azab, Abdel Kareem

“…Summary The phosphatidylinositide 3‐kinase (PI3K) pathway is activated and correlated with drug resistance in multiple myeloma (MM). In the present study we…”
Get full text

Patients with secondary acute myeloid leukemia undergoing allogeneic stem-cell transplant have inferior outcomes than de novo acute myeloid leukemia regardless minimal residual disease level by flow cytometry by Núñez-Torrón Stock, Claudia, Jiménez Chillón, Carlos, Martín Moro, Fernando, Marquet Palomanes, Juan, Velázquez Kennedy, Kyra, Piris Villaespesa, Miguel, Roldán Santiago, Ernesto, Rodríguez Martín, Eulalia, Chinea Rodríguez, Anabelle, García Gutiérrez, Valentín, Moreno Jiménez, Gemma, López Jiménez, Javier, Herrera Puente, Pilar

“…Secondary acute myeloid leukemia (s-AML) patients have a poor prognosis and currently the only curative therapy is allogeneic stem-cell transplant (HSCT)…”
Get full text

A prognostic model for survival after salvage treatment with FLAG‐Ida +/− gemtuzumab‐ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia by Bergua, Juan M., Montesinos, Pau, Martinez‐Cuadrón, David, Fernández‐Abellán, Pascual, Serrano, Josefina, Sayas, María J., Prieto‐Fernandez, Julio, García, Raimundo, García‐Huerta, Ana J., Barrios, Manuel, Benavente, Celina, Pérez‐Encinas, Manuel, Simiele, Adriana, Rodríguez‐Macias, Gabriela, Herrera‐Puente, Pilar, Rodríguez‐Veiga, Rebeca, Martínez‐Sánchez, María P., Amador‐Barciela, María L., Riaza‐Grau, Rosalía, Sanz, Miguel A.

“…Summary The combination of fludarabine, cytarabine, idarubicin, and granulocyte colony‐stimulating factor (FLAG‐Ida) is widely used in relapsed/refractory…”
Get full text

Cell culture in autologous fibrin scaffolds for applications in tissue engineering by de la Puente, Pilar, Ludeña, Dolores

“…In tissue engineering techniques, three-dimensional scaffolds are needed to adjust and guide cell growth and to allow tissue regeneration. The scaffold must be…”
Get full text

Mimicking tumor hypoxia and tumor-immune interactions employing three-dimensional in vitro models by Bhattacharya, Somshuvra, Calar, Kristin, de la Puente, Pilar

“…The heterogeneous tumor microenvironment (TME) is highly complex and not entirely understood. These complex configurations lead to the generation of…”
Get full text

The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy by Muz, Barbara, de la Puente, Pilar, Azab, Feda, Azab, Abdel Kareem

“…Hypoxia is a non-physiological level of oxygen tension, a phenomenon common in a majority of malignant tumors. Tumor-hypoxia leads to advanced but…”
Get full text

Differentiation within autologous fibrin scaffolds of porcine dermal cells with the mesenchymal stem cell phenotype by de la Puente, Pilar, Ludeña, Dolores, López, Marta, Ramos, Jennifer, Iglesias, Javier

“…Porcine mesenchymal stem cells (pMSCs) are an attractive source of cells for tissue engineering because their properties are similar to those of human stem…”
Get full text

Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy by Luderer, Micah John, de la Puente, Pilar, Azab, Abdel Kareem

“…Boron neutron capture therapy (BNCT) is a promising cancer therapy modality that utilizes the nuclear capture reaction of epithermal neutrons by boron-10…”
Get full text

PB1779: FLT3‐ITD MUTATION CHARACTERIZATION WITH CLASSICAL PCR METHODOLOGY VERSUS CAPTURE‐ AND AMPLICON‐BASED NGS PLATFORMS: A PETHEMA NGS‐AML PROJECT by Bilbao, Cristina, Stuckey, Ruth, Sargas, Claudia, Larráyoz, María J, Chillon, Maria Carmen, Diaz, Rosa Ayala, Carrillo, Estrella Cruz, Yébenes‐Ramírez, Manuel, Martinez‐Cuadron, David, Rodriguez‐Veiga, Rebeca, Gil, Cristina, Bernal, Teresa, Burgues, Juan Miguel Bergua, Algarra, Lorenzo, Tormo, Mar, Sanchez, Maria Pilar Martinez, Saldise, Elena Soria, Serrano, Josefina, Dominguez, Juan Manuel Alonso, Boyero, Raimundo Garcia, Amigo, Maria Luz, Herrera‐Puente, Pilar, Sayas, Maria J, Rubira, Esperanza Lavilla, Medina, Carlos Rodriguez, Sosa, Santiago Sánchez, Rodríguez‐Afonso, Jorge, Reyes‐González‐Casanova, Paula, Rodríguez‐Arbolí, Eduardo, Garcia, Joaquin Sanchez, Martinez‐Lopez, Joaquín, García‐Sanz, Ramón, Calasanz, Maria Jose, Barragan, Eva, Casares, Maria Teresa Gomez, Montesinos, Pau

Get full text

S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3‐ITD WILD‐TYPE AML by Montesinos, Pau, Rodríguez‐Veiga, Rebeca, Bergua Burgues, Juan Miguel, Algarra, Lorenzo, Botella, Carmen, Josè Antonio, Perez Simon, Bernal, Teresa, Tormo, Mar, Robles, Maria Calbacho, Salamero, Olga, Serrano, Josefina, Noriega, Victor, López‐López, Juan Antonio, Polo, Susana Vives, Colorado, Mercedes, Lorenzo, Jose Luis Lopez, Vidriales, María Belén, Boyero, Raimundo Garcia, Olave, Mayte, Herrera‐Puente, Pilar, Arce, Olga, Garcia, Manuel Barrios, Jose Sayas Lloris, Maria, Polo, Marta, Isabel Gomez Roncero, Maria, Barragan, Eva, Ayala Diaz, Rosa, Carmen Chillon, Maria, Jose Calasanz, Maria, Boluda, Blanca, Martinez‐Cuadrón, David, Labrador, Jorge

Get full text

Prevalence of Anisakiasis in Madrid (Spain) after 20 Years of Preventive Legislation by Blanco-Costales, Eva, González-Quevedo, Alejandra L, Lorenzo-Bernardo, Laura, de la Hoz-Martín, María P, Rodero, Marta, Puente, Pilar, Moreno-Torres, Irene, Cuéllar, Carmen, González-Fernández, Juan

“…Historical seroprevalence data for in Spain vary greatly depending on the sampling region owing to different fish consumption habits. As a result of European…”
Get full text

Leukemia Inhibitory Factor: An Important Cytokine in Pathologies and Cancer by Jorgensen, Megan M, de la Puente, Pilar

“…Leukemia Inhibitory Factor (LIF) is a member of the IL-6 cytokine family and is expressed in almost every tissue type within the body. Although LIF was named…”
Get full text